Collectively, these data supported the benefit of CD34+ selection for reduction of acute and chronic GVHD, albeit with high rates of infection for adults with hematological malignancies and graft failure in pediatrics, with no data for alternative donors, minimal for pediatric recipients, and other transplant indications. The gene discussed is CD34; the disease is graft versus host disease.